Dapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: study protocol for a multicenter, open-label, randomized controlled trial (the jDAPA-PD study)

Dapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: study protocol for a multicenter, open-label, randomized controlled trial (the jDAPA-PD study)

Abstract Background The effects of dapagliflozin on patients with end-stage kidney disease (ESKD) and chronic heart failure (CHF) who are on peritoneal dialysis (PD) are not well understood. The jDAPA-PD is a proof-of-concept study designed to assess the efficacy and safety of dapagliflozin in such...

Full description

Saved in:
Bibliographic Details
Main Authors: Mototsugu Tanaka, Masahiro Ishizawa, Ryohei Terashima, Atsushi Hashimoto, Takahiro Tanaka, Haruna Miyazawa, Kazuki Watanabe, Akira Iguchi, Hajime Yamazaki, Asa Ogawa, Noriaki Iino, Naoto Hamano, Ken Ataka, Suguru Yamamoto
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Renal Replacement Therapy
Subjects:
Body composition
Efficacy
End-stage kidney disease
Extracellular water
Fluid overload
Safety
Online Access:https://doi.org/10.1186/s41100-025-00647-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41100-025-00647-2

Similar Items